Reid Hoffman’s Manas AI raises $24.6M, a fraction of other AI drug discovery startups
LinkedIn founder Reid Hoffman and Siddhartha Mukherjee, cancer researcher and author of the book “The Emperor of All Maladies,” have co-founded an
Reid Hoffman Bets on A.I. Drug Discovery with a Pulitzer-Winning Cancer Physician
Hoffman isn’t the only prominent Silicon Valley figure betting on A.I.’s promise in medical research. The new technology is expected to generate between $60 billion and $110 billion annually in value for the pharmaceutical and medical-product industries, according to a McKinsey report released last year.
Reid Hoffman-backed AI drug discovery startup Manas AI launches with $24.6M
Manas AI Inc., a startup using artificial intelligence to discover new medicines, launched today with $24.6 million in initial funding. The investment was led by General Catalyst and Manas AI co-founder Reid Hoffman. Greylock Partners, where Hoffman was a general partner until 2023, participated as well.
LinkedIn founder launches AI start-up to revolutionize cancer drug discovery
LinkedIn co-founder Reid Hoffman and famed oncologist Dr. Siddhartha Mukherjee have raised a whopping $24.6 million in a seed funding round. The money will be used to launch their new artificial intelligence (AI) start-up, Manas AI.
Reid Hoffman Raises $24.6 Million for AI Cancer Research Startup
Tech investor and LinkedIn co-founder Reid Hoffman is teaming up with cancer researcher Siddhartha Mukherjee on an artificial intelligence drug discovery startup that is launching with $24.6 million of initial funding.
The Scientist4h
Schrödinger Selects Sapio Sciences to Enhance In Silico Drug Discovery From Plasmid to Structure
Configurable informatics platform improves lab efficiency, data tracking, and resource management from plasmid to structure ...
Crain's Chicago Business13h
Life sciences investor commits $130M to UChicago drug discovery
After striking similar deals with Northwestern and UIC, Deerfield Management aims to help the University of Chicago turn more ...
drugtargetreview.com1d
Obstacles and innovations of macrocyclic drug development
Discover the potential of macrocycles in drug discovery: flexible, cell-permeable molecules targeting undruggable proteins.
BioPharma Dive8h
Model Medicines Unveils Generative AI, Multi-Modal Therapeutic Pipeline Breakthrough, Demonstrating End-To-End Drug Discovery Capabilities
Multi-Modal Models: A multi-modal discovery approach was implemented that engineered-in potency against the novel target and engineered-out a specific off-target interaction. The NCE library displayed ...
Science Friday4d
AI Is Coming Up With Brand New Molecules, Fueling Drug Discovery
AI models are able to design molecules that don’t even exist in nature. Some have proven effective as snake antivenom.
Recursion Pharmaceuticals (RXRX): Industrializing Drug Discovery with AI Amid J.P. Morgan’s ‘Neutral’ Outlook
We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...
AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform
Longstanding relationship strengthens innovation, providing diverse stakeholders access to advanced AI-driven insights to accelerate therapeutic discovery and developmentGUILFORD, Conn., Jan. 28, 2025 ...
Manas AI Launches to Transform Discovery of Novel Cancer Medicines
Cofounded by Dr. Siddhartha Mukherjee and Reid Hoffman, Manas AI leverages proprietary AI, generative computational chemistry ...
Hosted on MSN11h
AI Pharma: 2 Paths to AI-Powered Drug Investment
The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...